Preliminary exploration of the selection strategy for essential medicines for children in China from an international perspective

SUN Yunlong; LAI Xin; TIAN Lei

doi:10.6039/j.issn.1001-0408.2025.21.01

您当前的位置：

首页 >

文章列表页 >

Preliminary exploration of the selection strategy for essential medicines for children in China from an international perspective

更新时间：2025-11-10

- Preliminary exploration of the selection strategy for essential medicines for children in China from an international perspective
- ZHONGGUO YAOFANG Vol. 36, Issue 21, Pages: 2621-2626(2025)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.21.01
  CLC： R95
- Received：20 January 2025，
  
  Revised：2025-06-22，
  
  Accepted：23 June 2025，
  
  Published：15 November 2025
- 稿件说明：
移动端阅览
孙云龙,赖欣,田磊.基于国际视角的我国儿童基本药物遴选策略初探[J].中国药房,2025,36(21):2621-2626.

SUN Yunlong,LAI Xin,TIAN Lei.Preliminary exploration of the selection strategy for essential medicines for children in China from an international perspective[J].ZHONGGUO YAOFANG,2025,36(21):2621-2626.
孙云龙,赖欣,田磊.基于国际视角的我国儿童基本药物遴选策略初探[J].中国药房,2025,36(21):2621-2626. DOI： 10.6039/j.issn.1001-0408.2025.21.01.

SUN Yunlong,LAI Xin,TIAN Lei.Preliminary exploration of the selection strategy for essential medicines for children in China from an international perspective[J].ZHONGGUO YAOFANG,2025,36(21):2621-2626. DOI： 10.6039/j.issn.1001-0408.2025.21.01.

摘要

目的

为更新完善我国现行基本药物目录体系，制定儿童专属基本药物目录，鼓励儿童用药研发生产，提高儿童用药可及性、安全性提供参考依据及实施路径。

方法

采用对比分析与描述性分析方法，对第9版《WHO儿童基本药物目录》（WHO EMLc）的药物分类、剂型规格、疾病谱覆盖及特殊标识等进行统计分析，并与2018年版《国家基本药物目录》（NEML）以及2016－2024年国家卫生健康委员会发布的5批《鼓励研发申报儿童药品清单》进行比较，综合评估第9版WHO EMLc药物在我国的可获得性。结果与

结论

两类目录差异较为明显，总体重合药物有101种，占第9版WHO EMLc药物总量的27.98%。第9版WHO EMLc相较于2018年版NEML，在儿童适宜药物种类多样性、剂型适配性及规格精准性等方面优势显著；《鼓励研发申报儿童药品清单》一定程度上填补了我国儿童用药的空缺，丰富了儿童用药品种和剂型选择，但其中未上市的药物占近80%，仍存在研发转化率偏低、政策激励效果不足等问题。建议结合我国国情，借鉴WHO和发达国家、地区儿童药物遴选经验，建立分级分类的儿童专属基本药物目录，加大对儿童适宜药物剂型、规格研发的支持力度，强化申报、审评、采购等全周期政策倾斜，鼓励开展儿童用药循证医学实践，加快儿童基本药物研发、上市及遴选进程，保障儿童用药可获得性。

Abstract

OBJECTIVE

To offer references and implementation paths for updating and enhancing the China’s current essential medicines list system， formulating a specific list of essential medicines for children in China，

promoting the research and development of pediatric medications， and improving the accessibility and safety of pediatric medications for children.

METHODS

Comparative and descriptive analysis was utilized to statistically analyze the classification， dosage forms， specifications， disease spectrum， and symbolic annotations of the 9th edition of

the WHO Model List of Essential Medicines for Children

（WHO EMLc）. Differences were compared among WHO EMLc， the 2018

National Essential Medicines List

（NEML）， and five batches of the

List of Encouraged R&D and Declaration of Pediatric Drugs

issued by the National Health Commission from

2016 to 2024. The availability of drugs in the 9th edition of WHO EMLc in China was discussed.

RESULTS &CONCLUSIONS

The differences between the two lists were relatively substantial. A total of 101 drugs overlapped， accounting for 27.98% of the total number of drugs in the 9th edition of the WHO EMLc. Compared with the 2018 NEML， the 9th edition of the WHO EMLc showed notable advantages in the diversity of pediatric-appropriate drug types， dosage form adaptability， and specification precision. The

List of Encouraged R&D and Declaration of Pediatric Drugs

， to some extent，

had filled the gap in China’s pediatric medications， enriching the variety of drug types and dosage forms for children. However， nearly 80% of the drugs on the list were not yet marketed， still facing problems such as a low R

D conversion rate and insufficient policy incentive effects. It is recommended to establish a tiered and classified pediatric essential medicines list based on China’s national conditions， drawing on the selection experience of the WHO and developed countries/regions； strengthen support for the R

D of appropriate pediatric dosage forms and specifications； implement policy preferences throughout the entire cycle of application， review and procurement； encourage evidence-based pediatric practices， accelerate the R

D， market launch， and selection processes of pediatric essential medicines， and ensure the accessibility of pediatric medicines.

关键词

Keywords

references

国家统计局，联合国儿童基金会，联合国人口基金 . 2020年中国儿童人口状况事实与数据 [EB/OL ] .[ 2024-12-18 ] . https：//www.stats.gov.cn/zs/tjwh/tjkw/tjzl/202304/t20230- 419_1938814.html https://www.stats.gov.cn/zs/tjwh/tjkw/tjzl/202304/t20230-419_1938814.html .

梁建章，黄文政，何亚福，等 . 中国生育成本报告2024版 [EB/OL ] . [ 2024-12-18 ] . https：//caoss.org.cn/upload/file/24031812405831.pdf https://caoss.org.cn/upload/file/24031812405831.pdf .

国家卫生健康委员会 . 国家基本药物目录：2018年版 [EB/OL ] .[ 2024-12-18 ] . https：//www.gov.cn/fuwu/2018-10/30/5335721/files/e7473e46d9b24aadad3eb25127ffd986.pdf https://www.gov.cn/fuwu/2018-10/30/5335721/files/e7473e46d9b24aadad3eb25127ffd986.pdf .

WHO . WHO model list of essential medicines for children：8th list [EB/OL ] . [ 2024-12-18 ] . https：//www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03 https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03 .

WHO . WHO model list of essential medicines for children：9th list [EB/OL ] .[ 2024-12-18 ] . https：//www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.03 https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.03 .

IHME . Global burden of disease 2021：findings from the GBD 2021 study [EB/OL ] . [ 2024-12-18 ] . https：//www.healthdata.org/research-analysis https://www.healthdata.org/research-analysis .

WHO . Executive summary of the report of the 24th WHO expert committee on selection and use of essential medicines [EB/OL ] . [ 2024-12-18 ] . https：//www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.01 https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.01 .

EDELMAN C M ， MEADOW S R ， et al . Childhood di- sease and disorder [EB/OL ] . [ 2024-12-18 ] . https：//www.britannica.com/science/childhood-diseases-and-disorders https://www.britannica.com/science/childhood-diseases-and-disorders .

国家卫生健康委员会 . 2023中国卫生健康统计年鉴 [M ] . 北京：中国协和医科大学出版社， 2023 ： 124 - 134 .

国家药品监督管理局 . 2023年度药品审评报告 [EB/OL ] . [ 2024-12-18 ] . https：//www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20240204154334141.html https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20240204154334141.html .

潘锋 . 改善儿童用药管理，保障儿童用药安全 [J ] . 妇儿健康导刊， 2023 （ 6 ）： 4 - 5 .

SHAH B A ， PATEL A S ， PATEL B ， et al . Mini-tablet drug delivery system for pediatric dosage form （PDF）： a review of manufacturing perspectives [J/OL ] . Int J Drug Dev Res ， 2018 ， 10 [ 2024-12-18 ] . https：//www.semanticscholar.org/paper/Mini-Tablet-Drug-Delivery-System-for-Pediatric-Form-Shah-Patel/9314923741d964dcc71df74f43762a8f9-d6c0df6 https://www.semanticscholar.org/paper/Mini-Tablet-Drug-Delivery-System-for-Pediatric-Form-Shah-Patel/9314923741d964dcc71df74f43762a8f9-d6c0df6 .

李勇，胡培杰，张乐彤 . 国内外儿童用药研发现状及激励政策比较 [J ] . 中国药物评价， 2023 ， 40 （ 1 ）： 12 - 16 .

李秀丽，李丹，瞿礼萍，等 . 欧盟儿科药品管理条例系统解析 [J ] . 中国药学杂志， 2024 ， 59 （ 12 ）： 1165 - 1170 .

丁锦希，任宏业，蒋蓉 . 日本临床急需儿童药品政策法规及启示研究 [J ] . 现代商贸工业， 2016 ， 37 （ 13 ）： 125 - 126 .

菅长永，董方玉，陈晨，等 . 中国血浆蛋白制品的展望 [J ] . 中国输血杂志， 2022 ， 35 （ 2 ）： 227 - 232 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

六省区18家二级医院国家基本药物（中成药）使用情况调研

Related Author

李晓玲王香平王育琴王晓燕彭迎春白向荣元华龙

Related Institution

No data

⁰